直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

At the PTAB Blog

USPTO Announces Voluntary Search Disclosure Declarations Initiative for PTAB Proceedings

November 19, 2025

Authored and Edited by Candace C. Walther; Jameson K. Gardner, Ph.D.; Forrest A. Jones

On November 17, the United States Patent and Trademark Office issued a memorandum announcing that petitioners in IPR and PGR proceedings before the Patent Trial and Appeal Board may voluntarily submit a Search Disclosure Declaration (SDD), which will be considered as a non-exclusive, non-dispositive favorable discretionary factor supporting institution. The new initiative is effective immediately and applies to all IPR and PGR proceedings in which a patent owner preliminary response due date has not yet elapsed. The initiative is designed to strengthen examination quality by improving the USPTO’s ability to locate relevant prior art during prosecution.

A petitioner may elect to submit an SDD explaining, in detail:

  • The databases and repositories in which the asserted prior art was located;
  • The general search approach, search terms, filters, queries, or classification pathways employed;
  • Other analytics or publicly accessible resources consulted;
  • The amount of time spent on the search; and
  • The amount of time spent reviewing search results.

In addition to the above, the SDD may also include any other information relevant to the search methodology employed.

This SDD may not be public, as a petitioner may file its SDD under seal for in camera review. In addition, the Office also noted that deposition testimony related to an SDD will not be permitted absent extraordinary circumstances. However, any proposed protective order must indicate that the Office may use the information in an SDD for internal training, improving examination processes, and analytics, where use by the Office is not precluded by law. In its alert announcing the new practice, the Office explained that information submitted in an SDD “will be used internally to enhance examiner training, refine classification pathways, and inform development of AI-enhanced search tools.”

The Office emphasized that a petitioner will not be disadvantaged for not submitting an SDD. However, the submission of an SDD will be a “favorable discretionary factor” in institution decisions, particularly when it “reveals new or underutilized pathways relevant to Office search practice,” or in helping demonstrate Office error during examination.

For new petitions, an SDD must be submitted as a standalone exhibit at the time the petition is filed. For currently pending petitions, a petitioner may file an SDD within seven business days of November 17, so long as the patent owner preliminary response deadline has not passed.

Tags

United States Patent and Trademark Office (USPTO)

Related Practices

Patent Office Invalidation Proceedings

PTAB Invalidation Proceedings: IPR and PGR

Related Offices

Atlanta, GA

Reston, VA

Washington, DC

Contacts

Candace C. Walther
Associate
Atlanta, GA
+1 404 653 6478
Email
Forrest A. Jones
Partner
Washington, DC
+1 202 408 4019
Email

Copyright © 2025 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 

DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.

Related Insights

At the PTAB Blog

Consistency Is Key – USPTO Issues Three New Informative Decisions

May 29, 2026

At the PTAB Blog

Discretion All the Way Down: USPTO Uses a Discretionary IPR Denial to Justify a    
§ 325(d) EPR Denial

May 28, 2026

Articles

Colorado Replaces Landmark AI Act: An Overview of the New SB 26-189 Framework

May 26, 2026

At the PTAB Blog

IPR and PGR Statistics for Final Written Decisions Issued in March and April 2026

May 26, 2026

At the PTAB Blog

Claim Disclaimer Derails Instituted IPR in Freightcar America

May 26, 2026

At the PTAB Blog

Before the Holding, the Message: Director Squires Uses Magnolia Medical to Outline PTAB Discretionary Denial Policy Changes

May 20, 2026

Conference

19th Annual Forum on Pharma & Biotech Patent Litigation in Europe

May 19-20, 2026

Amsterdam

Webinar

Changes at the PTAB from Settled Expectations to Real Parties in Interest to Director Involvement

May 18, 2026

Webinar

Seminar

IP Strategy at the Crossroads: Technology, Enforcement, and Contracts

May 15, 2026

Taipei

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP